Sarepta Therapeutics Inc (NASDAQ: SRPT) kicked off on Monday, down -5.04% from the previous trading day, before settling in for the closing price of $18.24. Over the past 52 weeks, SRPT has traded in a range of $16.88-$154.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -272.11%. With a float of $93.47 million, this company’s outstanding shares have now reached $98.25 million.
Let’s look at the performance matrix of the company that is accounted for 1372 employees. In terms of profitability, gross margin is 80.96%, operating margin of -5.25%, and the pretax margin is -7.35%.
Sarepta Therapeutics Inc (SRPT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sarepta Therapeutics Inc is 4.89%, while institutional ownership is 90.07%. The most recent insider transaction that took place on Mar 12 ’25, was worth 248,203. In this transaction Director of this company sold 2,491 shares at a rate of $99.64, taking the stock ownership to the 27,812 shares. Before that another transaction happened on Mar 12 ’25, when Company’s Director proposed sale 2,491 for $99.65, making the entire transaction worth $248,226.
Sarepta Therapeutics Inc (SRPT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -272.11% per share during the next fiscal year.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Trading Performance Indicators
Take a look at Sarepta Therapeutics Inc’s (SRPT) current performance indicators. Last quarter, stock had a quick ratio of 2.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit 0.67 in the next quarter and is forecasted to reach 2.79 in one year’s time.
Technical Analysis of Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ: SRPT) saw its 5-day average volume 4.42 million, a positive change from its year-to-date volume of 3.39 million. As of the previous 9 days, the stock’s Stochastic %D was 37.23%.
During the past 100 days, Sarepta Therapeutics Inc’s (SRPT) raw stochastic average was set at 0.46%, which indicates a significant decrease from 7.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 221.76% in the past 14 days, which was higher than the 129.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.59, while its 200-day Moving Average is $90.65. Nevertheless, the first resistance level for the watch stands at $17.96 in the near term. At $18.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.92. If the price goes on to break the first support level at $17.00, it is likely to go to the next support level at $16.67. Assuming the price breaks the second support level, the third support level stands at $16.04.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Key Stats
The company with the Market Capitalisation of 1.70 billion has total of 98,277K Shares Outstanding. Its annual sales at the moment are 1,902 M in contrast with the sum of 235,240 K annual income. Company’s last quarter sales were recorded 744,860 K and last quarter income was -447,510 K.
